The objective of this study was to assess the efficacy, safety, and tolerability of combination antivirals (amantadine/ribavirin/oseltamivir) versus oseltamivir alone for the treatment of influenza in an at-risk population. This study enrolled 881 participants worldwide, which were randomly selected in a 1:1 ratio to receive a blinded study treatment consisting of either the combination of amantadine, oseltamivir, and ribavirin or oseltamivir alone for 5 days. This study started on September 2010 and ended on March 2017. One of the outcomes was that combination treatment showed a significant decrease in viral shedding at day 3 relative to monotherapy, this difference was not associated with improved clinical benefit.